Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Significant progress has been made in prospectively designing molecules using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the analysis reported herein of a second wave of drug candidates that originated after the development and implementation of this tool. This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochemical properties. The CNS MPO tool has helped to increase the percentage of compounds nominated for clinical development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA). The use of this tool has played a role in reducing the number of compounds submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicology into First in Human studies. Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compounds nominated for clinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, A11 scores 4.8 out of 6 on the central nervous system multiparameter optimization (CNS MPO; Wager et al., 2016) desirability index, indicating favorable structural properties for CNS drug development (Fig. S4 d).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Wager et al., 2016
In the citing paper
“Clearly, molecular weight is a physicochemical parameter fundamental for CNS penetration and for the overall profile of drugs against neurodegenerative diseases.103,104”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100008c · Cited by 1,063
Self-citationPhysiochemical drug properties associated with in vivo toxicological outcomes
Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.071 · Cited by 946
Self-citationCNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure
Rankovic, Z. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501535r · Cited by 548
Wager, T. T., Chandrasekaran, R. Y., Hou, X., Troutman, M. D., Verhoest, P. R., Villalobos, A., & Will, Y. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100007x · Cited by 477
Self-citationGhose, A. K., Herbertz, T., Hudkins, R. L., Dorsey, B. D., & Mallamo, J. P. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200100h · Cited by 447
Feng, B., Mills, J. B., Davidson, R. E., Mireles, R. J., Janiszewski, J. S., Troutman, M. D., & de Morais, S. M. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017434 · Cited by 440
Development of a new permeability assay using low‐efflux MDCKII cells
Di, L., Whitney‐Pickett, C., Umland, J. P., Zhang, H., Zhang, X., Gebhard, D. F., Lai, Y., Federico, J. J., Davidson, R. E., Smith, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22674 · Cited by 313
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Ertl, P. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527621286.ch5 · Cited by 75
Research works printed but not linked: 1
- Harrington, E. C., Jr. (1965) The desirability function. Indust. Qual. Control 21, 494-498.
Cited by
Items 301–400 of 746
Empirical Analysis of Drug Targets for Nervous System Disorders
Mueller, L. G., Slusher, B. S., & Tsukamoto, T. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00676 · Cited by 9
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome
Baldwin, A. G., Foley, D., Collins, R. J., Lee, H.-A., Jones, D. H., Wahab, B., Waters, L., Pedder, J., Paine, M., Feng, G. J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02694 · Cited by 9
Mendes, F. R. D. S., de Sousa, D. S., da Rocha, M. N., Roberto, C. H. A., Marinho, M. M., dos Santos, H. S., & Marinho, E. S. (2025) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2025.100021 · Cited by 9
Preclinical tools for the evaluation of tuberculosis treatment regimens for children
Tucker, E. W., & Dooley, K. E. (2018) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.17.0354 · Cited by 9
Jakubiec, M., Abram, M., Zagaja, M. P., Andres‐Mach, M., Szewczyk, A., Latacz, G., Szulczyk, B., Socała, K., Nieoczym, D., Właź, P., et al. (2022) · Cells · doi:10.3390/cells11121862 · Cited by 9
“0 are widely used as a cut-off to select compounds for hit finding in CNS therapeutic area drug discovery programs [57].”
Cavalcante, C. H. L., Almeida-Neto, F. W. Q., da Rocha, M. N., Bandeira, P. N., de Menezes, R. R. P. P. B., Magalhães, E. P., Sampaio, T. L., Marinho, E. S., Marinho, M. M., Martins, A. M. C., et al. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2123394 · Cited by 9
“The estimate was supported by the bioavailability score (ABS) (Martin, 2005), built into the SwissADME online server (swissadme.ch) and by the multiparameter optimization (MPO) from Pfizer, Inc., (Wager et al., 2016) embedded in the MarvinSketchTM program (Csizmadia, 1999), leading the CPN2F to the absorption, distrib…”
BackgroundMethodInfluentialAdvances in Drug Discovery and Development in Geriatric Psychiatry
Conley, A. C., & NEWHOUSE, P. A. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0871-5 · Cited by 9
Discovery of Tricyclic Triazolo- and Imidazopyridine Lactams as M1 Positive Allosteric Modulators
Engers, J. L., Bender, A. M., Kalbfleisch, J. J., Cho, H. P., Lingenfelter, K. S., Luscombe, V. B., Han, C., Melancon, B. J., Blobaum, A. L., Dickerson, J. W., et al. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00311 · Cited by 9
Chopko, T. C., Han, C., Gregro, A. R., Engers, D. W., Felts, A. S., Poslusney, M., Bollinger, K. A., Morrison, R. D., Bubser, M., Lamsal, A., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.032 · Cited by 9
Kułaga, D., Jaśkowska, J., & Satała, G. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126667 · Cited by 9
Analysis of the uncharted, druglike property space by self-organizing maps
Takács, G., Sándor, M., Szalai, Z., Kiss, R., & Balogh, G. T. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10343-y · Cited by 9
Studies on Diketopiperazine and Dipeptide Analogs as Opioid Receptor Ligands
Nia, S. S., Hossain, M. A., Ji, G., Jonnalagadda, S. K., Obeng, S., Rahman, M. A., Sifat, A. E., Nozohouri, S., Blackwell, C., Patel, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115309 · Cited by 9
Auxiliary Discrminator Sequence Generative Adversarial Networks for Few Sample Molecule Generation
Tang, H., Long, J., Ji, B., & Wang, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01737 · Cited by 8
Beyond base camp: PI3K/mTOR inhibition for the treatment of pediatric high-grade gliomas
Duchatel, R. J., Savary, C., Germon, Z. P., Riley, M., Ziegler, D. S., Mueller, S., Jackson, E. R., & Dun, M. D. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf163 · Cited by 9
Lu, P.-C., Huang, Y.-A., Wali, N., Tseng, M., He, R., Chern, Y., Wei, T.-T., Shie, J., & Huang, J. J. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c14078 · Cited by 9
Chen, Y., Guo, X., & Xue, W. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104634 · Cited by 8
Shah, A. H., Suter, R. K., Gudoor, P., Doucet-O’Hare, T. T., Stathias, V., Cajigas, I., de la Fuente, M. I., Govindarajan, V., Morell, A. A., Eichberg, D. G., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab192 · Cited by 8
“MPO index was derived, and compounds stratified with an CNS-MPO index > 4 (a threshold that correlated well to clinical success of marketed CNS drugs).(12,27)”
BackgroundMethodNunes, P. H. D. S., de Freitas, T. S., Rocha, J. E., Pereira, R. L. S., Marinho, M. M., de Oliveira, M. R., Oliveira, L. S., Marinho, E. M., Marinho, E. S., Aquino, S. S., et al. (2022) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12785 · Cited by 8
“System Multiparameter Optimization (CNS MPO) from the pharmaceutical company Pfizer, Inc [32].”
BackgroundMethodInfluentialGelin, C. F., Stenne, B., Coate, H. R., Hiscox, A., Soyode-Johnson, A., Wall, J. L., Lord, B., Schoellerman, J., Coe, K. J., Wang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01916 · Cited by 8
Preclinical validation of a novel therapeutic strategy for choroid plexus carcinoma
Martin, B., Garman, T., Laramee, M., Wang, A., Zhang, X., Beck, E., Wilson, K. M., Klumpp-Thomas, C. A., McKnight, C. G., Xu, X. Y., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.016 · Cited by 8
An electrophilic fragment screening for the development of small molecules targeting caspase-2
Cuellar, M. E., Yang, M., Surendra, K., Zhang, Y., Zhu, H., Sun, H., Shen, M., Hall, M. D., Patnaik, S., Ashe, K. H., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115632 · Cited by 8
Capstick, R. A., Bollinger, S. R., Engers, J. L., Long, M. F., Chang, S., Luscombe, V. B., Rodriguez, A. L., Niswender, C. M., Bridges, T. M., Boutaud, O. G., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00249 · Cited by 8
Bischoff, F., Brandt, S. V., Viellevoye, M., Cleyn, M. A. J. D., Surkyn, M., Carbajo, R. J., Blanco, M. D., Wroblowski, B., Karpowich, N. K., Steele, R. A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02751 · Cited by 8
Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib
Pang, Y. K., Qi, L., Sergi, Z., Yu, G., 桑雪雨, Kim, O., Wang, H., Ranjan, A., Merchant, M., Oudit, B., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112283 · Cited by 8
Spyrou, B., Hungnes, I. N., Mota, F., Bordoloi, J., Blower, P. J., White, J. M., Ma, M., & Donnelly, P. S. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c01992 · Cited by 8
Cores, Á., Michalska, P., Pérez, J. M., Crisman, E., Gómez, C., Villacampa, M., Menéndez, J. C., & Leon, R. M. (2022) · Antioxidants · doi:10.3390/antiox11010112 · Cited by 8
“[31,32] by using six critical physicochemical properties, namely MW, logP, logD, TPSA, H-bond donors and pKa.”
MethodMao, Q., Zhang, B., Tian, S., Qin, W., Chen, J., Huang, X., Ye, X., Yang, H., Zhen, X.-C., Shui, W., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105795 · Cited by 8
Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on α-Synuclein and Tau Aggregation
Ramirez, E., Ganegamage, S. K., Min, S., Patel, H., Ogunware, A. E., Plascencia‐Villa, G., Alnakhala, H., Shimanaka, K., Tripathi, A., Wang, K., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00464 · Cited by 8
da Fonseca, A. M., Soares, N. B., Colares, R. P., de Oliveira, M. M., Oliveira, L. S., Marinho, G. S., de Lima, M. R. P., da Rocha, M. N., dos Santos, H. S., & Marinho, E. S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2163702 · Cited by 8
“…value in the order of (cid:0) 4.90 cm/s suggests a high passive intestinal permeability (Papp > 20 � 10 (cid:0) 6 cm/s in the biopharmaceutical classification sys-tem (Wager et al., 2016)), resulting in high human intestinal absorption (HIA), contrary to what is observed in bis-biflorin (Table 1).”
BackgroundResultInfluentialRamirez, E., Min, S., Ganegamage, S. K., Shimanaka, K., Sosa, M. G., Dettmer, U., Rochet, J., & Fortin, J. S. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.100938 · Cited by 8
Mezeiová, E., Janočková, J., Konecny, J., Kobrlová, T., Benková, M., Doležal, R., Prchal, L., Karasova-Zdarova, J., Soukup, O., & Korábečný, J. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104179 · Cited by 8
Ranković, Z. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01388 · Cited by 8
Luo, W., Garchitorena, K. M., Tweedie, D., Chau, C. H., Patel, C., Siegler, M. A., Vargesson, N., Hwang, I., Kim, S., Kim, D. S., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152428 · Cited by 7
Molecular glue degraders: Rational design, specificity engineering, and advanced delivery
Ma, L., Wang, N., Zhu, J., Wu, L., He, S., & Zhang, B. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.020 · Cited by 10
BBB-Permeable PROTACs: Where Do We Stand?
Francisco, S., Apprato, G., Sebastiano, M. R., Ermondi, G., & Caron, G. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00768 · Cited by 7
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
Conery, A. R., La, D. S., Alekseyenko, A. A., Marcoux, D., Bart, A. G., Harlow, M. L., Arsenault, P. R., Cantone, N. R., Casaubon, R. L., Constan, A., et al. (2026) · Nature · doi:10.1038/s41586-026-10998-3 · Cited by 7
Czett, D., Böddi, K., Nagy, V., Takátsy, A., Deli, J., Tone, P., Balogh, G. T., Vincze, A., & Agócs, A. (2022) · Molecules · doi:10.3390/molecules27154822 · Cited by 7
“In the test group, the TPSA values for the basic carotenol derivatives (1–5) and melatonin are below 120 Å2, which also meets the oral absorption rule and the blood-brain barrier (BBB) absorption criterion (TPSA < 90 Å2) [37].”
BackgroundADMET study and inhibition of Staphylococcus aureus efflux pumps by a synthetic p-aminochalcone
de Sousa, J. N., Barreto, J. D. A. F., Oliveira, F. A. D. A., Ferreira, J. H. L., Arcanjo, D. D. R., Nogueira, C. E. S., Marinho, M. M., dos Santos, H. S., Rolim, H. M. L., Siqueira-Júnior, J. P., et al. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101449 · Cited by 7
Epigenetic Inhibitors as Alzheimer’s Disease Therapeutic Agents
Yamashita, Y., Itoh, Y., Takada, Y., & Suzuki, T. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c23-00027 · Cited by 7
Rawling, M. J., Ray‐Sinha, A., Bestwick, M., Carter, M. K., Chahal, S. K., Chalmers, A. J., Elsey, D. J., Giddings, A. M., Gold, J., Henderson, S. H., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00279 · Cited by 7
Hagar, H. C., Fernández-Vega, V., Wang, K., Jordan, L. M. O., Shumate, J., Scampavia, L. D., Tapayan, A. S., Nguyen, H. M., Spicer, T., & Kuo, M. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100235 · Cited by 7
Macêdo, N. S., Silveira, Z. D. S., Dantas, D. M., Barbosa, C. R. D. S., Oliveira–Tintino, C. D. D. M., Tintino, S. R., Alencar, G. G., Siqueira, G. M., da Silva, T. F., Marinho, M. M., et al. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100816 · Cited by 7
Aliashrafzadeh, H., Liu, D., Alba, S. D., Akbar, I., Lui, A., Vanleuven, J., Martin, R. M., Wang, Z., & Liu, D. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008116 · Cited by 7
“For example, other than using Lipinski’s guidelines to design oral small-molecule drugs, Pfizer chemists have provided a more focused CNS multiparameter optimization (MPO) score to guide BBB-penetrating small-molecule discovery [620, 621].”
CNSGT: Generative Transformer for De Novo Drug Design Targeting the Central Nervous System
Chen, Y., Luo, D., Chen, S., Hou, T., Huang, C., & Xue, W. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01541 · Cited by 7
Collins, J. W., Abedi, M., Ramirez, D. M. C., Philippe-Venec, L., Moore, B., & Asher, J. O. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01888 · Cited by 8
Dömling, A. S. S., Zheng, Q., & Boltjes, A. (2021) · Synthesis · doi:10.1055/s-0040-1706642 · Cited by 7
Olekšák, P., Psotka, M., Vančurová, M., Sapega, O., Bieblová, J., Reiniš, M., Rysanek, D., Mikyšková, R., Chalupova, K., Maliňák, D., et al. (2021) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1871336 · Cited by 7
Cleghorn, L. A. T., Wall, R. J., Albrecht, S. J. ‐., MacGowan, S. A., Norval, S., Rycker, M. D., Woodland, A., Spinks, D., Thompson, S., Patterson, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00509 · Cited by 7
Discovery and Characterization of Novel CNS-Penetrant GPR55 Agonists
Hewer, R. C., Christie, L. A., Doyle, K. J., Xu, X., Roberts, M. J., Dickson, L., Cheung, T., Cadwalladr, D., Pickford, P., Teall, M. R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00784 · Cited by 7
Shalgunov, V., van den Broek, S. L., Andersen, I. V., Raval, N. R., Schäfer, G. G., Barz, M., Herth, M. M., & Battisti, U. M. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108877 · Cited by 7
Knight, W., Margaryan, T., Sanai, N., & Tovmasyan, A. G. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116150 · Cited by 7
Lela, L., Ponticelli, M., Carlucci, V., Stevens, J. F., Faraone, I., Tzvetkov, N. T., & Milella, L. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c00532 · Cited by 7
Poslusney, M. S., Salovich, J. M., Wood, M. R., Melancon, B. J., Bollinger, K. A., Luscombe, V. B., Rodriguez, A. L., Engers, D. W., Bridges, T. M., Niswender, C. M., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.039 · Cited by 7
Phenothiazines as dual inhibitors of SARS-CoV-2 main protease and COVID-19 inflammation
Forrestall, K. L., Burley, D. E., Cash, M. K., Pottie, I. R., & Darvesh, S. (2021) · Canadian Journal of Chemistry · doi:10.1139/cjc-2021-0139 · Cited by 7
Millard, M., Kilian, J., Ozenil, M., Mogeritsch, M., Schwingenschlögl-Maisetschläger, V., Hölzer, W., Hacker, M., Langer, T., & Pichler, V. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115891 · Cited by 7
Ku, T. C., Cao, J., Won, S. J., Guo, J., Camacho‐Hernandez, G. A., Okorom, A. V., Salomon, K., Lee, K. H., Loland, C. J., Duff, H. J., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00322 · Cited by 7
Provencher, B. A., Eshleman, A. J., Johnson, R. A., Shi, X., Kryatova, O. P., Nelson, J. K., Jianhua, T., Gonzalez, M., Meltzer, P. C., & Janowsky, A. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00542 · Cited by 7
da Silva, H. C., Monteiro, A. D. O., Almeida-Neto, F. W. Q., Marinho, E. M., Ferreira, M. K. A., Mendes, F. R. D. S., Marinho, E. S., Marinho, M. M., Bezerra, L. L., da Rocha, M. N., et al. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2029771 · Cited by 7
“12, ChemAxon (https://chemaxon. com/products/marvin) and applied to the drug-likeness filters of Lipinski’s “rule of five” (Lipinski, 2004) and Veber’s rule (Veber et al., 2002) embedded in the SwissADME platform (http://www.swissadme.ch/) and then transformed into druglikeness scores by the Central Nervous System Mul…”
Method1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists
van der Straat, R., Draijer, R., Surmiak, E., Butera, R., Land, L., Magiera‐Mularz, K., Musielak, B., Plewka, J., Holak, T. A., & Dömling, A. S. S. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00746d · Cited by 6
Pereira, A. M. G., de Oliveira, V. M., da Rocha, M. N., Roberto, C. H. A., Cajazeiras, F. F. M., Guedes, J. M., Marinho, M. M., Teixeira, A. M. R., Marinho, E. S., de Lima‐Neto, P., et al. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01200-y · Cited by 6
“According to Pfizer, Inc.'s biopharmaceutical classification system, compounds with low lipophilicity exhibit better alignment between P app MDCK > 10 × 10 -6 cm/s and CL int,u 8.0 mL/min/kg (high permeability and low clearance) [40, 47].”
InfluentialNunes, J. V. S., da Rocha, M. N., de Oliveira, V. M., Roberto, C. H. A., dos Santos, H. S., Marinho, E. S., Marinho, M. M., & Martins, A. M. C. (2024) · ChemistrySelect · doi:10.1002/slct.202402673 · Cited by 6
Lemke, J., Mengers, N., Schmidt, L., Schulig, L., König, S., Rosendahl, P., Bartz, F., Garscha, U., Bednarski, P. J., & Link, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03112 · Cited by 6
Gammal, A., Nassar, T., Soae, Y., Freeman, N., Badihi, A., Baraghithy, S., Nemirovski, A., Tam, J., & Benita, S. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03132 · Cited by 6
Phenol and chromone compounds for in silico inhibition of nsP2 and nsP3 of Chikungunya virus
Lima, J. P. O., Roberto, C. H. A., da Rocha, M. N., de Oliveira, V. M., Freire, R. M., Santos‐Oliveira, R., Marinho, E. S., de Lima‐Neto, P., & Fechine, P. B. A. (2025) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2025.100084 · Cited by 6
“As described by Wager and coworkers [47], more polar (40 TPSA ≤ 90 Å 2 ), less lipophilic (logP ≤ 3), less basic and larger than commercially available drugs from data sets, including from Pfizer [48], are less likely to be toxic in the nervous system in vivo .”
Romão, I. C., Alves, A. M. B., Silva, T., Marinho, M. M., Marinho, E. S., da Rocha, M. N., Dias, J. M. L., Fernandes, G. C., Pinto, F. D. C. L., Gomes, A. C., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152728 · Cited by 6
de Sousa, D. S., de Oliveira, V. M., Gomes, A. O. C. V., Mendes, F. R. D. S., Marinho, M. M., de Lima‐Neto, P., & Marinho, G. S. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00437-y · Cited by 6
“The study of latency to the acetylcholinergic receptor was based on the CNS MPO (Central Nervous system Multiparameter Optimization) algorithm from Pfizer, which establishes similarity in the structure–activity relationship (QSAR) of pharmacophores (Wager et al. 2010, 2016).”
Illuminating proinflammatory myeloid cells with PET tracers targeting GPR84
Kalita, M., Kuo, R., Straniero, V., Reyes, S. T., Pandrala, M., Lanzini, A., Marsango, S., D’Moore, D., Mahn, P., Setiadi, A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536372123 · Cited by 6
Identification of Psychoplastogenic Tropanes Lacking Muscarinic Activity
Warren, H. T., Chow, W. L., Chytil, M., Rasmussen, K., & Olson, D. E. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01204 · Cited by 6
In Silico Prediction of CNS Bioavailability
Talevi, A. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_4 · Cited by 6
da Silva, H. C., Pinto, F. D. C. L., Marinho, E. S., de Menezes, J. E. S. A., Ferreira, M. K. A., da Silva, A. W., Marinho, E. M., Marinho, M. M., de Menezes, R. R. P. P. B., Cavalcante, J. W., et al. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202401207 · Cited by 6
Mordyl, B., Fajkis-Zajączkowska, N., Szafrańska, K., Siwek, A., Głuch‐Lutwin, M., Żmudzki, P., Jończyk, J., Karcz, T. P., Słoczyńska, K., Pękala, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01578 · Cited by 6
Stalińska, J., Houser, L., Rak, M., Colley, S. B., Reiss, K., & Jursic, B. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-53207-0 · Cited by 6
Zhou, Y., Hu, Y., Lü, X., Yang, H., Li, Q., Du, C., Chen, Y., Hong, K. H., & Sun, H. (2020) · Dose-Response · doi:10.1177/1559325820938526 · Cited by 6
“Central nervous system multiparameter optimization (MPO) score is now a well-recognized algorithm in the CNSfocused medicinal chemistry community.(32) In our study, we performed virtual screens of 2 CNS-targeted libraries, Enamine CNS Library (47 040 compounds) and ChemDiv CNS-MPO Library (29 872 compounds), which are…”
Agarwal, P., Ishida, K., Reid, D. L., & Gupta, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.10.008 · Cited by 6
Costa, W. D., Mendes, F. R. D. S., Almeida-Neto, F. W. Q., Marinho, E. S., Barreto, A. C. H., Morais‐Braga, M. F. B., Guedes, J. M., Marinho, M. M., Julião, M. S. D. S., Canuto, K. M., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138117 · Cited by 6
Influence of Descriptor Implementation on Compound Ranking Based on Multiparameter Assessment
Sosnina, E. A., Osolodkin, D. I., Radchenko, E. V., Sosnin, S., & Palyulin, V. A. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00734 · Cited by 6
Valko, K. L. (2020) · Handbook of analytical separations · doi:10.1016/b978-0-444-64070-3.00013-8 · Cited by 6
Teichman, E. M., Hu, J., Lin, H.-Y., Fisher-Foye, R. L., Blando, A., Hu, X., Kaniskan, H. Ü., Montgomery, S. E., Cai, M., Parise, L. F., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02972-8 · Cited by 5
da Silva, B. F., Pereira, A. M. G., Araújo, I. M. F., Aguiar, F. K. C., Cajazeiras, F. F. M., Gomes, A. O. C. V., Marinho, M. M., Teixeira, A. M. R., Marinho, E. S., Costa, R. A., et al. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107230 · Cited by 5
Ta, G. H., & Leong, M. K. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110366 · Cited by 5
Tarai, A., Mitra, T., Pain, T., Mallick, J., Chakraborty, R., Tejaswi, K., Ghatak, S., & Kar, S. (2026) · Advanced Science · doi:10.1002/advs.202515462 · Cited by 5
M^4olGen: Multi-Agent, Multi-Stage Molecular Generation under Precise Multi-Property Constraints
Li, Y., Cloutier, F., Wu, S., Parviz, A., Knyazev, B. A., Zhang, Y., Berseth, G., & Liu, B. (2026) · doi:10.18653/2026.findings-aacl.236 · Cited by 5
Hasan, H. A., Radhi, A. J., & Alaridhee, Z. A. I. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.145964 · Cited by 5
Tibbs, G. R., Uprety, R., Warren, J. D., Beyer, N. P., Joyce, R. L., Ferrer, M. A., Mellado, W., Wong, V. S. C., Goldberg, D. C., Cohen, M. W., et al. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.06.067 · Cited by 5
Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma
Patrón, L. A., Yeoman, H., Wilson, S., Tang, N., Berens, M. E., Gokhale, V. M., & Suzuki, T. C. (2024) · Biomedicines · doi:10.3390/biomedicines12020406 · Cited by 5
“To improve the drug-like and physiochemical properties of our molecules, we designed and synthesized a series of analogs optimized for low molecular weight, low polar surface area, and a good CNS multiparametric optimization (MPO) score [9].”
Method5-HT6 receptor neutral antagonists protect astrocytes: A lesson from 2-phenylpyrrole derivatives
Drop, M., Koczurkiewicz, P., Bento, O., Pietruś, W., Satała, G., Blicharz-Futera, K., Canale, V., Grychowska, K., Bantreil, X., Pękala, E., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116615 · Cited by 5
Hackney, J. F., Broatch, J., Dallal, R. A., Brotherson, C., Livingston, S., Sabir, Z. L., Reshi, S. M., Petras, S. R. F., Mallick, S., Applegate, M. T., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00286 · Cited by 5
Afzal, O., Alamri, M. A., Altharawi, A., Alossaimi, M. A., Mohamed, M. A., Altamimi, A. S. A., Asfour, H. Z., Alhakamy, N. A., & Firoz, A. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2472402 · Cited by 5
“22.19), ChemAxon Ltd. (Wager et al., 2016).”
InfluentialBdair, H., Singleton, T. A., Ross, K., Jolly, D., Kang, M. S., Aliaga, A., Tuznik, M., Kaur, T., Yous, S., Soucy, J., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00678 · Cited by 5
Ingraham, C. H., Stalińska, J., Carson, S. C., Colley, S. B., Rak, M., Lassak, A., Peruzzi, F., Reiss, K., & Jursic, B. S. (2023) · Scientific Reports · doi:10.1038/s41598-023-39236-w · Cited by 5
Nunes, J. V. S., Marinho, E. M., Roberto, C. H. A., de Menezes, R. R. P. P. B., Magalhães, E. P., Ribeiro, L. R., da Rocha, M. N., Almeida-Neto, F. W. Q., Monteiro, M. L., Marinho, E. S., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139124 · Cited by 5
Rapacz, A., Jakubiec, M., Abram, M., Jasiński, J., Chrzan, K., Góra, M., Dziubina, A., Wójcik‐Pszczoła, K., Koczurkiewicz, P., Ciepiela, K., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17111532 · Cited by 5
“Furthermore, Instant JChem by ChemAxon software version 23.14 was used to compute the central nervous system multiparameter optimization (CNS MPO) score (Table 1) [22].”
InfluentialHunter, J., Valle, L. D., Peruzzi, F., & Reiss, K. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70045 · Cited by 5
“To address these challenges, we have synthetically altered the chemical structure of fenofibrate (FF) by assessing physicochemical properties that enable new compounds to achieve enhanced penetration of the BBB (Stalinska et al. 2019; Stalinska et al. 2022; Wager et al. 2010, 2016).”
Structure–property studies of an imidazoquinoline chemotype with antitrypanosomal activity
Klug, D. M., Díaz-González, R., DeLano, T. J., Mavrogiannaki, E. M., Buskes, M. J., Dalton, R. M., Fisher, J. K., Schneider, K. M., Hilborne, V., Fritsche, M. G., et al. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00103a · Cited by 5
de Sousa, D. S., da Silva, M. V. F., da Fonseca, A. M., Paiva, M. M. C. C., Salmito-Vanderley, C. S. B., & Marinho, G. S. (2025) · Steroids · doi:10.1016/j.steroids.2025.109705 · Cited by 4
The utility of 2,5-dimethoxy-4-iodoamphetamine for the study of serotonin 2A and 2C receptors
Cameron, L. P., Jaster, A. M., Ramos, R., & Ullman, E. Z. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100093 · Cited by 4
Alkhatib, M., Jakobs, F. M., Hanson, J. N., Nilson, A. N., Moritz, A. E., Li, T., Faibille, A. B., Bourn, L. A., Ramdhan, P., Ricchezza, J., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00646 · Cited by 4
Opportunities and Challenges in Precision Neurotherapeutics
Mujica-Parodi, L. R., Öngür, D., & Richardson, R. M. (2026) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-110824-031709 · Cited by 4
Grossman, S. A., Barone, A. K., Strowd, R. E., III, Rais, R., Duke, E., Wearne, E., Price, L., Hendrix, C. W., Schreck, K. C., Lesser, G. J., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag051 · Cited by 4
Lin, S., Xia, W., Nagata, Y., & Yang, H. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-23604-3_2 · Cited by 4
Metadata
- Authors
- Wager, T. T., Hou, X., Verhoest, P. R., & Villalobos, A.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Wager, Travis T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-03-18
- Volume
- 7
- Issue
- 6
- Pages
- 767-775
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2300160852
- Cited by
- 653
- References
- 13
- Citations by year
- 2026: 104 · 2025: 121 · 2024: 103 · 2023: 75 · 2022: 72 · 2021: 45 · 2020: 37 · 2019: 32 · 2018: 40 · 2017: 19 · 2016: 5
- FWCI
- 30.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- ACS Chemical Neuroscience (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- desirability function, drug candidate design, ADME properties, blood-brain barrier permeability, ClogP, topological polar surface area, drug safety, drug discovery
- MeSH terms
- Algorithms, Animals, Biological Transport, Blood-Brain Barrier, Central Nervous System, Humans, Permeability, Drug Design, ATP Binding Cassette Transporter, Subfamily B, Member 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.